Birgitta Stymne Göransson elected member of LEO Pharma’s Board of Directors
BALLERUP, Denmark, November 14, 2019 – LEO Pharma A/S today announced that Birgitta Stymne Göransson has been elected member of the company’s Board of Directors.
Birgitta Stymne Göransson has worked as non-executive Boardmember, Chairman and Committee Chair of several boards and audit committees and has more than 25 years of experience in medtech and IT/tech as well as consulting, consumer retail and branded goods.
Birgitta Stymne Göransson’s current chairmanships include BCB Medical Oy and Industrifonden in Sweden as well as Chair of the Audit Committees of Elekta AB and Pandora AS. In her previous executive roles, she has among other worked as Industrial Advisor to Ratos AB, and held positions as Chief Executive at Memira Holding AB and Semantix Group AB.
Olivier Bohuon, Chairman of the Board of Directors at LEO Pharma A/S, says: “We are pleased to welcome Birgitta Stymne Göransson to the Board of Directors. With her broad industry insights and deep financial experience from both public and private companies, she will play an important role in the realization of LEO Pharma’s ambitious growth strategy.”
Birgitta Stymne Göransson holds an MBA from Harvard Business School, MA, USA as well as a M.Sc. in Chemical Engineering and Biotechnology from the Royal Institute of Technology in Sweden.
Trine Juul Wengel
Global External Communications, LEO Pharma A/S
Tel.: (+45) 20732037
About LEO Pharma
About LEO Pharma A/S
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit.
Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma strengthens global leadership team30.6.2020 12:43:59 CEST | Press release
Ballerup, June 30, 2020 – LEO Pharma, a global leader in medical dermatology, today announced that Dr. Monica Shaw, M.D., and Nathalie Joannes will join the executive leadership team adding seasoned experience and international profile to LEO Pharma.
LEO Pharma presents results from study of twice-weekly Enstilar® (calcipotriene and betamethasone dipropionate) Foam for topical use in long-term maintenance treatment of plaque psoriasis12.6.2020 21:20:42 CEST | Press release
New results from the PSO-LONG clinical trial are the first to provide long-term maintenance data for plaque psoriasis with a twice-weekly topical treatment with Enstilar®(calcipotriene and betamethasone dipropionate) Foam Plaque psoriasis is a chronic, multifactorial disease affecting nearly 80% of the 125 million people living with psoriasis worldwide(1,2) LEO Pharma is committed to building on its more than 30-year heritage of pursuing innovative products for patients affected by psoriasis and other chronic skin conditions BALLERUP, Denmark, JUNE 12, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today presented results from the Phase 3 PSO-LONG clinical trial. PSO-LONG compared the efficacy and safety of twice-weekly Enstilar® (calcipotriene and betamethasone dipropionate)Foam, versus foam vehicle for long-term (52-week) maintenance treatment for adult patients with plaque psoriasis.(3,4) Results were presented as ePosters online at the American Academy of Dermatolog
Tralokinumab achieves primary and secondary endpoints in three pivotal Phase 3 trials in adult patients with moderate-to-severe atopic dermatitis12.6.2020 21:06:15 CEST | Press release
Presented at the AAD VMX 2020, results from ECZTRA 1, 2 and 3 trials confirm tralokinumab met its primary and secondary endpoints and are the first Phase 3 results in atopic dermatitis for an investigational therapy that specifically targets IL-13 Tralokinumab demonstrated statistically significant improvements in outcomes including pruritus (itch) and health-related quality of life measures that are important to patients In ECZTRA 1 and 2, the majority of patients treated with tralokinumab 300 mg every two weeks who achieved a clinical response at week 16, maintained response at week 52 without any use of topical corticosteroids In ECZTRA 3, nine out of 10 patients who achieved clear or almost clear skin with tralokinumab 300 mg in combination with topical corticosteroids at week 16 maintained this response at week 32 when randomized to dosing every two weeks. Similarly, eight out of 10 patients randomized to dosing every four weeks at week 16 maintained clear or almost clear skin at
LEO Pharma announces European Medicines Agency acceptance of marketing authorization application for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis11.6.2020 14:00:00 CEST | Press release
BALLERUP, Denmark, JUNE 11, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today announced that the European Medicines Agency (EMA) validated the marketing authorization application (MAA) for tralokinumab, an investigational product for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD). The acceptance of this MAA marks the beginning of the formal review procedure for this potential new treatment by the EMA’s Committee for Medicinal Products for Human Use (CHMP).
LEO Pharma Presents Phase 3 Data in Atopic Dermatitis and Plaque Psoriasis at the American Academy of Dermatology Virtual Meeting Experience 20202.6.2020 14:00:00 CEST | Press release
-- Data include pivotal efficacy and safety clinical trials of tralokinumab monotherapy and tralokinumab with concomitant topical corticosteroid use in adult patients with moderate-to-severe atopic dermatitis --
LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate15.4.2020 07:45:16 CEST | Press release
BALLERUP, Denmark, April 15, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today announced that is has signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan, TPEx: 4743) and Microbio Shanghai (China) covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom